Cerus Announces New Supply Agreement With Largest Blood Service In Saudi Arabia

Cerus Corporation (NASDAQ: CERS) announced today that Al Shalan, Cerus’ exclusive distributor for Saudi Arabia, has signed a three-year agreement with the King Faisal Specialist Hospital, a leading medical center in Saudi Arabia, to supply the INTERCEPT Blood System for platelets. This contract allows for the routine use of INTERCEPT to treat up to 100% of the hospital’s platelet production of approximately 5,600 units annually.

“We believe that our superior technology and demonstrated ability to satisfy demanding national blood service customers were critical to the decision by the King Faisal Specialist Hospital,” said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “Given the institutions’s position as a thought leader in the Middle East, we believe that its choice of INTERCEPT will influence future blood safety technology decisions throughout the region.”

King Faisal Specialist Hospital is one of the top three reference medical centers serving the Saudi capital of Riyadh. Saudi Arabia has an estimated national production of approximately 70,000 platelet units and 100,000 plasma units per year.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

1 2 Next › Last »